RNAZ (TransCode Therapeutics) Operating Income: $-32.71 Mil (TTM As of Mar. 2026)


RNAZ TransCode Therapeutics Inc RNAZ
34 GF Score
Price $8.37
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Operating Income?

TransCode Therapeutics RNAZ +8.62% 34 Operating Income is $-32.71 Mil as of Mar. 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

TransCode Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-17.62 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-32.71 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. TransCode Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-17.62 Mil. TransCode Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, TransCode Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was %.

TransCode Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TransCode Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -50.04%. TransCode Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -19,558.77%.

TransCode Therapeutics  (NAS:RNAZ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TransCode Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-70.46 * ( 1 - 0% )/( (141.091 + 140.502)/ 2 )
=-70.46/140.7965
=-50.04 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=162.399 - 3.494 - ( 17.814 - max(0, 3.494 - 21.984+17.814))
=141.091

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=157.165 - 5.293 - ( 12.835 - max(0, 5.379 - 16.749+12.835))
=140.502

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TransCode Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-70.216/( ( (0.371 + max(-0.277, 0)) + (0.347 + max(-1.466, 0)) )/ 2 )
=-70.216/( ( 0.371 + 0.347 )/ 2 )
=-70.216/0.359
=-19,558.77 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.217) - (3.494 + 0 + 0)
=-0.277

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.913) - (5.293 + 0.085 + 0.00099999999999945)
=-1.466

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

TransCode Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.615/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

TransCode Therapeutics Operating Income Related Terms

TransCode Therapeutics Operating Income Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics Operating Income Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial -5.87 -17.55 -18.50 -15.14 -17.92

TransCode Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -4.07 -4.54 -6.49 -17.62
RNAZ
34GF Score
TransCode Therapeutics Inc RNAZ
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-32.71 Mil mean?
TransCode Therapeutics (RNAZ) has a Operating Income of $-32.71 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on TransCode Therapeutics and its competitors.
Is TransCode Therapeutics' Operating Income too high?
TransCode Therapeutics' current Operating Income is $-32.71 Mil. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Operating Income compare to ENSC and ALZN?
TransCode Therapeutics' Operating Income of $-32.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current Operating Income is $-32.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Operating Income of $-32.71 Mil. The current Operating Income is $-32.71 Mil. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Operating Income is $-32.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score

Get the complete analysis for RNAZ

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.37
Price